SERMs, including tamoxifen (Tam), the first AE used successfully for breast cancer treatment, inhibit activity of ERs in a tissue and gene-specific manner, exerting partial agonist effects on ER-mediated transcription. The gene discussed is ESR1; the disease is breast carcinoma.